Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.67 |
| ▸ | HRH1 | P35367 | 1/20 | 0.67 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889370 | 0.84 | — | — | |
| SCHEMBL2626827 | 0.83 | AOC3 (0.62) | HRH4HRH1FDPSAOC3TSHR | |
| SCHEMBL20939170 | 0.83 | HRH3 (0.52) | HRH4HRH1TSHRALDH1A1MEN1 | |
| SCHEMBL889085 | 0.82 | — | — | |
| SCHEMBL889023 | 0.82 | — | — | |
| SCHEMBL906338 | 0.82 | — | — | |
| SCHEMBL1035880 | 0.80 | — | — | |
| 2-Methylhistamine SCHEMBL889086 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL3583087 | 0.80 | — | — | |
| SCHEMBL889061 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HRH4 4195/4885HRH1 3197/4885FDPS 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.